Patients and Methods
Patients and Tissues
Statistical Analysis
Results
Total | N0 (n = 789) | N1/N2 (n = 455) |
p value | HR (95 % CI) | |
---|---|---|---|---|---|
Gender | |||||
Male | 560 (45.0 %) | 327 (41.4 %) | 233 (51.2 %) | 0.001 | 1.282 (1.108–1.483) |
Female | 684 (55.0 %) | 462 (58.6 %) | 222 (48.8 %) | ||
Age | |||||
< Average | 598 (48.1 %) | 360 (45.6 %) | 238 (52.3 %) | 0.023 | 1.185 (1.023–1.372) |
≥ Average | 646 (51.9 %) | 429 (54.4 %) | 217 (47.7 %) | ||
Smoking status | |||||
Former/current | 403 (32.4 %) | 225 (28.5 %) | 178 (39.1 %) | <0.001 | 1.340 (1.159–1.553) |
Never | 841 (67.6 %) | 564 (71.5 %) | 277 (60.9 %) | ||
Tumor locationa
| |||||
LUL | 330 (26.5 %) | 193 (24.5 %) | 137 (30.1 %) | 0.033 | 0.838 (0.717–0.979) |
LLL | 200 (16.1 %) | 119 (15.1 %) | 81 (17.8 %) | 0.208 | 0.885 (0.734–1.066) |
RUL | 406 (32.6 %) | 274 (34.7 %) | 132 (29.0 %) | 0.038 | 1.186 (1.006–1.397) |
RML | 103 (8.3 %) | 64 (8.1 %) | 39 (8.6 %) | 0.777 | 0.963 (0.743–1.248) |
RLL | 231 (18.6 %) | 150 (19.0 %) | 81 (17.8 %) | 0.597 | 1.053 (0.868–1.277) |
LVI | |||||
Yes | 203 (16.3 %) | 35 (4.4 %) | 168 (36.9 %) | <0.001 | 3.003 (2.674–3.378) |
No | 1041 (83.7 %) | 754 (95.6 %) | 287 (63.1 %) | ||
Differentiation | |||||
Well | 169 (13.6 %) | 153 (19.4 %) | 16 (3.5 %) | <0.001 | 0.232 (0.145–0.372) |
Moderate | 714 (57.4 %) | 492 (62.4 %) | 222 (48.8 %) | <0.001 | 0.707 (0.612–0.818) |
Poor | 361 (29.0 %) | 144 (18.3 %) | 217 (47.7 %) | <0.001 | 2.232 (1.946–2.558) |
Tumor size (cm) | |||||
< 3 | 756 (60.8 %) | 572 (72.5 %) | 184 (40.4 %) | <0.001 | 2.283 (1.965–2.646) |
≥ 3 | 488 (39.2 %) | 217 (27.5 %) | 271 (59.6 %) | ||
Predominant subtype | |||||
L | 158 (12.7 %) | 154 (19.5 %) | 4 (0.9 %) | <0.001 | 0.061 (0.023–0.161) |
A | 598 (48.1 %) | 211 (46.4 %) | 387 (49.0 %) | 0.363 | 0.935 (0.806–1.082) |
P | 170 (13.7 %) | 98 (12.4 %) | 72 (15.8 %) | 0.092 | 1.188 (0.979–1.441) |
M | 68 (5.5 %) | 35 (4.4 %) | 33 (7.3 %) | 0.035 | 1.353 (1.046–1.748) |
S | 171 (13.7 %) | 62 (7.9 %) | 109 (24.0 %) | <0.001 | 1.976 (1.715–2.278) |
IMA | 72 (5.8 %) | 48 (6.1 %) | 24 (5.3 %) | 0.556 | 0.907 (0.648–1.267) |
Minor components | |||||
L | 109 (8.8 %) | 94 (11.9 %) | 15 (3.3 %) | <0.001 | 0.355 (0.221–0.571) |
A | 196 (15.8 %) | 123 (15.6 %) | 73 (16.0 %) | 0.832 | 1.021 (0.838–1.247) |
P | 178 (14.3 %) | 97 (12.3 %) | 81 (17.8 %) | 0.008 | 1.297 (1.083–1.553) |
M | 105 (8.4 %) | 49 (6.2 %) | 56 (12.3 %) | <0.001 | 1.522 (1.252–1.852) |
S | 210 (16.9 %) | 103 (13.1 %) | 107 (23.5 %) | <0.001 | 1.513 (1.292–1.773) |
IMA | 62 (5.0 %) | 34 (4.3 %) | 28 (6.2 %) | 0.150 | 1.250 (0.941–1.661) |
The Predictive Value of Lymph Node Metastasis
Subtype | Negative (%)a
| Minor component (%) |
p value | Predominant (%) |
p value |
---|---|---|---|---|---|
L | 17.5 | 5.2 | <0.001 | 8.2 | <0.001 |
A | 16.6 | 15.6 | 0.650 | 15.5 | 0.233 |
P | 15.9 | 19.5 | 0.106 | 20.1 | 0.081 |
M | 15.6 | 25.2 | 0.002 | 23.8 | 0.066 |
S | 14.9 | 24.0 | <0.001 | 28.7 | <0.001 |
IMA | 16.2 | 21.4 | 0.138 | 14.7 | 0.580 |
Subtype | Negative (%)a
| Minor component (%) |
p value | Predominant (%) |
p value |
---|---|---|---|---|---|
L | 11.4 | 3.1 | <0.001 | 6.3 | <0.001 |
A | 10.8 | 10.1 | 0.663 | 9.8 | 0.176 |
P | 10.5 | 11.9 | 0.397 | 13.5 | 0.081 |
M | 10.1 | 17.3 | 0.004 | 17.5 | 0.056 |
S | 9.7 | 15.5 | 0.001 | 18.0 | <0.001 |
IMA | 10.6 | 12.7 | 0.441 | 9.7 | 0.687 |
Does Each Subtype Predict a Different Prognosis?
Subtype | OR | 95 % CI |
p value |
---|---|---|---|
Recurrence-free survival | |||
Lepidic | 1.361 | 0.905–2.041 | 0.139 |
Acinar | 1.104 | 0.83–1.453 | 0.485 |
Papillary | 0.978 | 0.752–1.271 | 0.866 |
Micropapillary | 0.524 | 0.388–0.708 | <0.001 |
Solid | 0.728 | 0.567–0.936 | 0.014 |
Invasive mucinous carcinoma | 1.351 | 0.883–2.066 | 0.165 |
Overall survival | |||
Lepidic | 1.730 | 0.878–3.413 | 0.113 |
Acinar | 1.122 | 0.754–1.669 | 0.571 |
Papillary | 1.284 | 0.861–1.912 | 0.220 |
Micropapillary | 0.585 | 0.385–0.890 | 0.012 |
Solid | 0.690 | 0.484–0.982 | 0.039 |
Invasive mucinous carcinoma | 0.870 | 0.519–1.456 | 0.594 |